A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
Open Access
- 21 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 33 (1), 329-335
- https://doi.org/10.1080/09546634.2020.1752888
Abstract
Background: Factors beyond the Psoriasis Area and Severity Index (PASI) contribute to disease severity in psoriasis and potentially affect treatment responses. Objective: This subset analysis of data from two phase 3 clinical studies assessed baseline parameters in patients with different degrees of psoriasis severity in order to determine treatment responses to ixekizumab and safety outcomes. Methods: This study used integrated data from the UNCOVER-2 and -3 trials involving 2709 patients with chronic plaque psoriasis to assess the efficacy and safety of ixekizumab in three subgroups of patients, defined by PASI > 15 (group 1), PASI > 15 and history of ≥3 non-biologic systemic therapies (group 2), or PASI = 12-15 (group 3). Results: In groups 1 and 2, additional baseline features were identified that could influence treatment responses, including age at disease onset, Dermatology Life Quality Index, and work productivity. Irrespective of subgroup, ixekizumab demonstrated high PASI responses at weeks 12 and 60, which were evident as early as week 2. Adverse events did not differ across subgroups. Conclusion: Our data support the efficacy, early onset of action, and maintained response of ixekizumab as observed in previous trials, and highlight the complexity of comprehensively defining disease severity in psoriasis.Keywords
This publication has 20 references indexed in Scilit:
- Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Journal of Dermatological Treatment, 2016
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisThe New England Journal of Medicine, 2016
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsThe Lancet, 2015
- Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective studyJournal of Dermatological Treatment, 2013
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisThe New England Journal of Medicine, 2012
- Role of IL-17 in Psoriasis and Psoriatic ArthritisClinical Reviews in Allergy & Immunology, 2012
- LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept studyArthritis & Rheumatism, 2010
- Consecutive use of different biological therapies in the treatment of psoriasisBritish Journal of Dermatology, 2007
- Adverse events from systemic therapies for psoriasis are common in clinical practiceJournal of Dermatological Treatment, 2006
- A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patientsDermatology Online Journal, 2004